Press Releases Suven Life Sciences Limited NSE India S.E.

Equities

SUVEN

INE495B01038

Market Closed - NSE India S.E. Other stock markets 07:43:49 2024-05-03 am EDT			5-day change	1st Jan Change
113.8 ^INR	+0.84%		+2.06%	+40.87%

Apr. 15	Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA	CI
Feb. 06	Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Suven Life Sciences : October 30, 2023Suven Life Sciences announces Positive Topline Results from a Phase-2 study evaluating Samelisant	23-10-30	PU
October 24, 2023Suven Life Sciences Announces Scientific Presentation at CTAD-2023: Study Design of Global Phase-3	23-10-24	PU
Suven Life Sciences : July 17, 2023Suven Life Announces Clinical and Preclinical data Poster Presentations at AAIC 2023, Amsterdam.	23-07-17	PU
Suven Life Sciences : Form MGT-7 FY 2022-23	23-07-15	PU
Suven Life Sciences : Annual Report FY 2022-23 (Book)	23-07-12	PU
Suven Life Sciences : Annual Report 2022-2023	23-07-12	PU
Suven Life Sciences announces two poster presentations including patient baseline characteristics and demographics from the phase-2 Proof of Concept study on samelisant at the SLEEP-2023 annual meeting	23-06-05	AQ
Suven Life Sciences : June 03, 2023Suven announces two poster presentations from the phase-2 (PoC) study on samelisant (SUVN-G3031)	23-06-03	PU
Suven Life Sciences : June 01, 2023Suven completed enrollment of patients to the phase-2(PoC) clinical study of SUVN-G3031 in US,CANADA	23-06-01	PU
Suven Life Sciences : Schedule of Conference Call for Investors on May 26, 2023	23-05-19	PU
Suven Life Sciences : Outcome of the Board Meeting	23-03-01	PU
Suven Life Sciences : Schedule of Conference Call for Investors on February 7, 2023	23-01-31	PU
Suven Life Sciences : Conference Call Transcript on December 26, 2022	22-12-30	PU
Suven Life Sciences : Schedule of Conference Call for Investors on December 26, 2022	22-12-28	PU
Suven Life Sciences : Disclosure under Regulation 30	22-12-28	PU
Suven Life Sciences Presenting Study Design and Initiation of Phase-3 Global Clinical Trial of 'Masupirdine (SUVN-502)	22-11-30	AQ
Suven Life Sciences : November 29, 2022Suven Presenting Study Design,Initiation of Phase-3 Global Clinical Trial of Masupirdine (SUVN-502)	22-11-29	PU
Suven Life Sciences : Newspaper Advertisements	22-11-23	PU
Suven Life Sciences Limited Announces Randomization of First Patient in Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type	22-11-17	AQ
Suven Life Sciences : Rights Issue	22-11-16	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Suven Life Sciences Limited NSE India S.E.

Equities

SUVEN

INE495B01038

Press Releases

Filters